Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Anemia rises but falls by end of treatment period in pivotal COMFORT-1 trial.
You may also be interested in...
Incyte’s Jakafi Gets Broad Label, Early Approval For Myelofibrosis
Incyte Corp. hits the trifecta – a first-in-class, first-in-disease and first launch with the Nov. 16 FDA approval of Jakafi (ruxolitinib) for treatment of the progressive bone marrow cancer.
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.
With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis
No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.